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Introduction: It is important to determine the relation among the
various lesions in patients presenting with multiple malignant lung
tumors to define the best treatment approach. A better understanding
of the molecular alterations present in the different lesions may help
in defining this relation.
Methods: We performed a detailed molecular analysis of several
tumor specimens obtained from three patients presenting with mul-
tiple lung lesions. Tumor specimens were analyzed for epidermal
growth factor receptor (EGFR) and k-ras mutations by direct DNA
sequencing. In addition, a genome-wide chromosomal copy number
analysis was performed on DNA extracted from the various lesions
using array-based comparative genomic hybridization.
Results: In one case, a deletion of 15 base pairs in exon 19 of EGFR
was present in all tumor sites analyzed. Furthermore, a similar
pattern of chromosomal aberrations was observed among the various
lesions, suggesting that they share the same clonal origin. In the
other two cases, in contrast, we identified distinct k-ras genotypes
among the various lesions from the same patient. These lesions,
moreover, showed different chromosomal aberration patterns,
indicating that they may have different underlying pathways of
tumorigenesis.
Conclusion: Our results show that EGFR and k-ras mutation anal-
ysis, combined with chromosomal copy number profiling, can help
in defining the relationship among different tumors in one patient.
Key Words: Non-small cell lung cancer, Microarray-based com-
parative genomic hybridization, Epidermal growth factor receptor,
k-ras.
(J Thorac Oncol. 2007;2: 12–21)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer death in the United States and in Western
Europe. Most patients with NSCLC are candidates for sys-
temic therapy at some point in the course of the disease.
Particular molecular tumor characteristics can be of
help in deciding on systemic treatment. For example, certain
mutations in the epidermal growth factor receptor (EGFR)
and k-ras genes have been shown to correlate with either
favorable or unfavorable patient response, respectively, to
treatment with the EGFR tyrosine kinase inhibitors gefitinib
and erlotinib.1–3
Patients with NSCLC are at relatively high risk of
developing secondary primary lung tumors, depending on
stage at initial diagnosis, with percentages ranging from
3% to 14%.4–6 Lungs are moreover a major site of metas-
tases from common solid tumors. Among patients with
multiple lung tumors, the clonal relation of the various
tumors is important in deciding on treatment. Histopatho-
logical examinations of the multiple lesions are often not
conclusive as to the differential diagnosis of second pri-
mary or metastasis, and a more extensive examination of
the genomic changes that occur may help in this diagnosis.
In this regard, microarray-based comparative genomic hy-
bridization (array-CGH), which measures DNA copy num-
ber changes throughout the entire genome, can provide
important diagnostic information.7–9
We performed a detailed genetic analysis of tumor
samples obtained from three patients with multiple malignant
lung lesions using EGFR and k-ras mutation analysis com-
bined with array CGH, which allowed identification of clonal
relationships among the various lung lesions.
CASE REPORTS
Patient 1
In April 2003, a 29-year-old man presented to his
primary care physician with thoracic pain and hemoptysis. He
had a performance status of 0 and showed no weight loss.
Physical examination showed no abnormalities. Besides leu-
kocytosis (12·4 109/L), laboratory values were normal. The
patient had no significant medical history and used no med-
ication. He worked as a professional mason and was a very
light smoker (smoking history, 1 pack-year).
A computed tomography (CT) scan of the thorax
showed a right lower lobe mass. Subsequently, a diagnosis of
pneumonia was made, but no clinical or radiographic im-
provement was observed, despite treatment with antibiotics.
Because of persistent hemoptysis, a bronchoscopy was per-
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FIGURE 1. Localization and molecular analysis of tumors from patient 1. (A) A schematic illustration of localization and time
of diagnosis of multiple malignant lung lesions in patient 1. (B) Computed tomographic scans of the thorax show lesion 1 in
the right lung before and after chemoradiation, and lesion 2 and 3 in the left lung. (C) Genome wide profiles of tumor sites 2
and 3. Tumor DNA of patient 1 was hybridized with normal female reference DNA on a 30K human oligonucleotide array. On
the X axis, array elements are ordered according to their position on the genome. Odd and even chromosomes are indicated
in light and dark blue, respectively. On the Y axis, ratios are plotted as log2 ratio of the fluorescent intensities of tumor (Cy3)
divided by reference (Cy5) signal for each element on the array. Smoothed values are indicated in red. A smoothed log2 ratio
close to zero indicates no difference in fluorescence intensity between tumor and reference DNA and, hence, no chromosomal
copy number aberrations. Log2 ratios greater or lower than zero indicate gains or losses of chromosomal elements, respec-
tively. For patient 1, similar patterns of chromosomal aberrations can be observed for tumor sites 2 and 3, indicating that
these lesions share the same clonal origin.
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formed and showed no endobronchial lesions. The CT scan of
the thorax was repeated and revealed the known lesion in the
right lower lobe and two enlarged mediastinal lymph nodes;
i.e., mediastinal nodal station 4R and 7. The lesion in the right
lower lobe and mediastinal lymph nodes had uptake on a
[18FDG] positron emission tomography (PET) scan. Cytolog-
ical analysis of the subcarinal lymph node, obtained by an
Endoscopic Ultrasound-Fine Needle Aspiration, showed ad-
enocarcinoma. The tumor was staged as IIIaN2 non-small
cell lung carcinoma (T2N2M0). The patient was treated using
a chemoradiation protocol of platinum-based chemotherapy
and definite thoracic radiotherapy. After treatment, a CT scan
and a [18FDG] PET scan were repeated. CT scan of the thorax
showed a partial response of the lesion (Figure 1B). [18FDG]
PET scan showed no uptake in the primary lesion and
minimal uptake in a subcarinal lymph node. Biopsies of
mediastinal lymph nodes obtained by mediastinoscopy
showed no malignant cells, and the patient underwent an R0
bilobectomy. Histological analysis revealed residual adeno-
carcinoma at the primary tumor site and no detectable tumor
in hilar and mediastinal lymph nodes. The patient recovered
well after surgery. No adjuvant therapy was administered.
In February 2005, the patient again reported slight
hemoptysis. A CT scan showed two small lesions in the
left lung: one in the left lower lobe and one in the left
upper lobe. These two lesions, as well as two left hilar
lymph nodes, were positive on an [18FDG] PET scan. The
lesion in the left lower lobe appeared radiologically com-
patible with a second primary tumor, and was actually
already visible on the CT scans performed before the
operation in 2003. At that time this was not considered to
be a tumor because of the lack of FDG avidity and the lack
of change after induction chemotherapy (Figure 1B). The
patient underwent a segmental resection of the left upper
lobe, a segmental resection of the left lower lobe, and
mediastinal lymph node dissection (stations 4, 5, 8, and
10) in May 2005. Histological analysis showed poorly
differentiated adenocarcinoma in both lung nodules and
two mediastinal lymph nodes (5 and 10) contained meta-
static adenocarcinoma. Postoperatively, he underwent
three cycles of cisplatin and vinorelbine. A tyrosine kinase
inhibitor of EGFR was administered after chemotherapy.
The patient is well without evidence of disease more than
1 year after the operation.
FIGURE 1. (Continued ).
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Patient 2
In May 2005, a 48-year-old woman was referred by her
primary care physician because of persisting cough. A radio-
graph of the chest showed two contralateral pulmonary le-
sions. She was in a good clinical condition and had no weight
loss. Physical examination revealed no abnormalities. Be-
sides a mild increase in the erythrosedimentation rate (27
mm) and leukocytosis (13.3 109/L), laboratory values were
normal. The patient had a smoking history of 35 pack-year
and used fluoxetine for depression. Her medical and family
histories were negative for malignancy.
A CT scan of the thorax showed a cavitating lesion in
the right upper lobe and a solid lesion in the left lower lobe
(Figure 2B). There were no mediastinal lymphadenopathies.
Pulmonary function tests and diffusion capacity were normal.
Bronchoscopy showed no endobronchial lesions; cytologic
evaluation of a broncho-alveolar lavage of the left lower lobe
identified adenocarcinoma cells. A [18FDG] PET-scan
showed the two pulmonary lesions and a hot spot in the right
lobe of the thyroid gland. Histological analysis of the thyroid
lesion revealed a papillary thyroid carcinoma.
In June 2005, the patient underwent complete resection of
the thyroid gland and resection of the cervical lymph nodes. On
histopathological evaluation of the resection specimens, a pap-
illary thyroid carcinoma of 8 mm was found, whereas all
resected lymph nodes were negative for malignancy.
Because the postoperative 131I scanning showed no
uptake in the pulmonary nodules and the early stage of the
papillary thyroid carcinoma, a tentative diagnosis of double
tumor (adenocarcinoma of the lung and papillary thyroid
carcinoma) was made.
In August 2005, patient 2 was referred to our hospital
and a [18FDG] PET scan showed only uptake in both pulmo-
nary lesions. In September 2005, a wedge resection of the
tumor in the right upper lobe was performed. Pathological
analysis showed moderately differentiated adenocarcinoma
of the lung. Immunohistochemical staining for thyroglobulin
was negative. In October 2005, the lower lobe of the left lung
FIGURE 2. Localization and molecular analysis of tumors from patient 2. (A) Schematic illustration of localization and time of
diagnosis of the various malignant lung lesions of patient 2. (B) Computed tomographic scans of the thorax. Lesion 2 can be
observed in the right lung and lesion 3 in the left lung. (C) Chromosomal aberration plots are depicted of lesion 2 and 3. Tu-
mor DNA of patient 2 was hybridized with normal male DNA on a 6K human BAC array. Log2 ratios are displayed against
their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. Smoothed values
are indicated in red. The chromosomal aberration patterns differ between tumor site 2 and 3. In particular, site 3 shows a log2
ratio of –0.35 at chromosome 3, 6, 9, 10, and 14q (arrows), these areas have a lower intensity of fluorescence in tumor DNA
versus reference DNA, indicating that these chromosomal regions are deleted. The smoothed log2 ratio of 1.4 on chromo-
some 14p (arrow) indicates that this chromosomal area has a high copy number in comparison to the reference DNA. These
narrow, high-level gains are referred to as amplification.21 Thus, in patient 2, less chromosomal aberrations are present in site
2 versus site 3, indicating they arose from different clones.
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and lymph nodes 7 to 11 were also resected. Pathology again
showed a moderately differentiated adenocarcinoma of the
lung with no positive staining for thyroglobulin. All resected
lymph nodes appeared free of malignancy. The patient recov-
ered well from both resections. Five months after the latter
operation, the patient presented with neurological symptoms,
and brain metastases were diagnosed. She underwent whole-
brain radiotherapy and eventually died of her disease.
Patient 3
A 65-year-old woman with a 50 pack-year history of
smoking was seen by her family physician in February 1997
because of mild dyspnea on exertion, asthenia, and fatigue.
A radiograph of the chest revealed a 3-cm lesion in the
right lower lobe, which was confirmed on CT scan of the
thorax. The lesion was not radiologically typical for malig-
nancy, and there were no lymphadenopathies. A CT scan
after 5 months showed no increase in the dimension of the
lesion. A [18FDG] PET scan showed minimal uptake in the
lesion in the right lower lobe but increased uptake in several
mediastinal lymph nodes. No endobronchial lesions were
seen on bronchoscopy, and cytology of broncho-alveolar
lavage revealed no malignant cells. Lymph node biopsies
obtained by mediastinoscopy showed no malignant cells. A
thoracotomy was performed in March 1998, and the lesion in
the right lower lobe was resected. Intraoperative pathological
analysis revealed papillary adenocarcinoma, and the surgical
procedure was limited to a lobectomy of the right lower lobe
(pT2N0M0).
Postoperatively, the patient experienced continuous
thoracic pain, which was resistant to several pain medica-
tions. Entrapment of an intercostal nerve as a result of callus
formation after the surgical procedure, which might benefit of
a partial resection of ribs 6 and 7, was considered a potential
cause for her pain. A new CT scan of the thorax showed two
subpleural lesions in the right lung in November 2002. One of
these two lesions was positive on a [18FDG] PET scan. A
partial resection of ribs 6 and 7 was performed, and a wedge
resection of the two aforementioned lesions in the right lung
was performed in March 2003. Pathological analysis showed
papillary adenocarcinoma of the lung, which was radically
FIGURE 2. (Continued ).
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resected. No adjuvant therapy was undertaken. Unfortu-
nately, the resection of ribs 6 and 7 did not have the desired
palliative effect on the patient’s thoracic pain.
A CT scan performed in January 2006 showed multiple
intrapulmonary lesions in the right and left lungs. Patholog-
ical examination of a CT-guided biopsy confirmed papillary
adenocarcinoma. The patient consented to an investigational
treatment with bevacizumab and erlotinib. After four courses
of therapy, she had signs of disease progression, and protocol
treatment was halted. She is currently alive with disease.
MATERIALS AND METHODS
Samples
Tumor specimens obtained before therapy were col-
lected, and informed consent was obtained from all patients.
Paraffin-embedded tissue blocks were cut into 4 m-thick
sections and placed onto glass slides. Slides were stained with
hematoxylin and eosin, and a pathologist (GAM) verified the
presence of tumor cells.
Mutation Analysis of EGFR and k-ras Genes
Isolation of genomic DNA and nested polymerase
chain reactions (PCR) were performed to amplify exon 18-21
of EGFR and exon 1-2 of k-ras, as previously described.10
Sequencing of PCR products was performed using the Big-
Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA), with the ABI PRISM 3100 Genetic
analyzer (Applied Biosystems). Mutations were confirmed by
sequencing independent PCR products. In doubtful cases, the
PCR product was cloned into the pGEM-T easy Vector
(Promega Benelux BV, Leiden, The Netherlands), and sev-
eral independent clones were sequenced.
Array Comparative Genomic Hybridization
DNA isolation from paraffin-embedded material was
performed as previously described.11 DNA labeling and hy-
bridization on CGH BAC and oligonucleotide microarrays
was performed as described by van den Ijssel et al.12 In short,
genomic DNA (300 ng) was labeled with Cy3-dCTP (tumor
sample) or Cy5-dCTP (reference sample of the opposite sex)
(Perkin Elmer, Boston, MA). Labeled, precipitated DNA was
dissolved in a hybridization mixture and hybridized to the
30K human oligo (patient 1 and 3) or to a 6K human BAC
(patient 2) array using a GeneTAC/HybArray12 hybstation
(Genomic Solutions; Perkin Elmer). Slides were scanned
using a Microarray Scanner G2505B (Agilent Technologies,
Palo Alto, CA). Log2 ratios were calculated with moving
average and are displayed against their position on the ge-
nome. Smoothed values were calculated using the January
2005 version of array CGH smooth.13
RESULTS
Case 1
Tumor localizations and CT scans of patient 1 are
shown in Figure 1A and B. In March 2005, two lesions
were observed in the left lung (2 and 3). In retrospect,
lesion 2 was already visible at diagnosis in 2003 and did
not respond to chemotherapy. EGFR and k-ras mutation
analyses were performed on tumor samples from sites 1, 2,
and 3, as well as on tumor cells from lymph nodes number
5 and 10. All tumor sites analyzed contained the same
heterozygous, in-frame deletion of 15 base pairs in exon 19
of the EGFR gene, leading to the deletion of amino acids
E746 to A750. This deletion affects the ATP-binding
pocket and is related to favorable response to treatment
with EGFR tyrosine kinase inhibitors.1,2 All sites analyzed
were wild type for k-ras. Although pathological examina-
tion suggested metastatic adenocarcinoma, the tumors in
the left lung were radiologically compatible with being
second primaries. To gain better insight into the relation of
the various lesions, array CGH was performed. Because of
the small number of tumor cells left in site 1, this analysis
was performed on tumor sites 2 and 3 only. Profiles of the
genetic aberrations are depicted in Figure 1C . Log2 tumor
to normal DNA copy number ratios are plotted in genomic
order. The aberrations are spread over the whole genome
and follow a nearly identical pattern of gains and losses in
both sites, indicating that these tumors share the same
clonal origin.
Case 2
In Figure 2A and B, a schematic diagram of the local-
ization and CT scans of the tumors are presented. The clinical
presentation of this patient suggested two independent lung
lesions. However, pathological and immunohistochemical
examination could not distinguish between second primary
and metastasis. Mutation analysis was performed on tumor
material of the thyroid (site 1), the right upper lobe (site 2),
and the left lower lobe (site 3). No mutations in the EGFR
gene were found in any of the sites analyzed. Tumor cells of
sites 1 and 2 were wild type for k-ras. In contrast, a point
mutation in codon 12 of k-ras leading to an amino acid
change from glycine to valine (G12V) was detected in the
tumor cells of site 3.
Array CGH analysis was performed on tumor material
from the two lung lesions (sites 2 and 3). As shown in Figure
2 C, the array CGH profiles of these two lesions differ for
almost all of the 22 chromosomes. In site 3, losses on
chromosomes 3, 6, 9, 10, and 14 and an amplification on
chromosomes 14p can be observed, whereas in tumor 2, these
aberrations are not present.
Case 3
A schematic representation of the tumor sites and CT
scans of patient 3 are shown in Figure 3A and B. Pathological
examination revealed papillary adenocarcinoma with the
same morphology in all tumor sites, which suggests that this
is most probably a metastasizing tumor. Mutational analysis
of EGFR and k-ras was performed on tumor cells from site 1,
2, and 4. All three lesions were wild type for EGFR. Sites 1
and 2 were also wild type for k-ras, whereas a point mutation
(G12V) in this gene was detected in site 4. Because k-ras
mutations may be an early event in tumorigenesis,14,15 the
k-ras mutation present only in this site suggests that site 4
could be a new primary tumor. Array CGH was performed on
tumor sites 1, 2, and 4. As shown by the smoothed patterns in
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Figure 3C, very few chromosomal aberrations are present in
site 4, whereas in sites 1 and 2, similar patterns of gains and
losses can be observed. In particular, gains of 6p and 7p and
loss of 6q present in sites 1 and 2 are absent in tumor site 4
(Figure 3D).
DISCUSSION
To identify the optimal treatment in patients with mul-
tiple lung tumors, the correct diagnosis of primary versus
secondary tumors is essential. Routine clinical and patholog-
ical evaluation to determine the relationship between the
different lesions often is not fully conclusive and a detailed
genetic analysis of tumor samples (e.g., for detection of gene
mutations, amplifications, or deletions) may provide impor-
tant additional information.
In this article, we describe three patients with NSCLC
who presented with multiple lesions and the results of genetic
analysis of their tumor samples. The analysis included direct
sequencing to detect EGFR and k-ras gene mutations and
array CGH to obtain tumor-specific DNA copy number sig-
natures. Previous groups have established that CGH is a
valuable tool in determining clonal relations between primary
tumors and their metastases of the breast,16 bladder,17 colon,18
and lung.19 Other such studies used loss of heterozygosity-
FIGURE 3. Localization and molecular analysis of tumors from patient 3. (A) Localization and time of diagnosis of the various
malignant lung lesions of patient 3. (B) Computed tomography scans of the thorax in which lesions 1, 2, 3, and 4 can be ob-
served. (C) Chromosomal aberration patterns of site 1, 2, and 4. Tumor DNA of patient 3 was hybridized with normal male
reference DNA on a 30K human oligonucleotide array. Log2 ratios are displayed against their position on the genome. Odd
and even chromosomes are indicated in light and dark blue, respectively. Smoothed values are indicated in red. The chromo-
somal aberrations of tumor 1 and 2 follow a similar pattern, suggesting they share the same clonal origin. The pattern of
chromosomal aberrations of tumor site 4 differs at various sites compared with tumor site 1 and 2, most obviously at chromo-
some 6 and 7 (arrows). (D) In site 1, the log2 ratios of chromosome 6p, 6q, and 7p are 0.08, 0.22, and 0.15, respec-
tively. In site 2, the log2 ratios of chromosome 6p, 6q, and 7p are 0.13, 0.18, and 0.12, respectively. Site 4, however,
shows a log2 ratio of 0.01 for chromosome 6p-q, and the log2 ratio for chromosome 7p is zero. Because tumor site 4 has a
much less altered chromosomal aberration pattern, it is likely that tumor 4 originated from a different clone than tumors 1
and 2.
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based techniques.8 Using this technique, only limited regions
of the genome are compared with identify a clonal relation.
We applied array-based CGH, capable of a genome-wide
screening for copy number aberrations, with high resolution
and high sensitivity.7
The same EGFR mutation was found in all lesions in
patient 1. In addition, nearly identical patterns of gains and
losses could be observed in lesions 2 and 3. The results of the
mutation analysis and the array CGH are consistent with
tumors 2 and 3 being metastatic lesions arising from tumor 1.
This would also support the view that the occurrence of
EGFR mutations is an early event in NSCLC tumorigenesis.20
In patient 2, clinical diagnosis suggested the presence of two
independent tumors. This hypothesis is strengthened by the
FIGURE 3. (Continued )
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FIGURE 3. (Continued ).
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results of the molecular analysis. The dissimilar chromo-
somal aberration pattern and the different k-ras mutational
status suggest that lesions 2 and 3 are most probably not
clonally related and may have genetically different underly-
ing pathways of tumor development. For patient 3, the results
of the array CGH analysis suggest that lesions 1 and 2, but
not 4, are clonally related. Thus, whereas lesion 2 (2002)
could be a metastasis from lesion 1 (1998), it is most likely
that lesion 4 (2006) arose independently. As described in
patient 2, the possibility of a different tumorigenic pathway
driving the development of tumor 4 is further supported by
the fact that a k-ras mutation was only detected in this lesion.
In summary, we show that, by using mutation analysis
of EGFR and k-ras combined with array CGH, we were able
to identify clonal relations among multiple tumors in one
patient. Our findings suggest that, in patients presenting with
multiple lung lesions, various underlying molecular mecha-
nisms can be responsible for tumor development. The pre-
dictive value of specific mutations in EGFR and k-ras genes
has already brought us one step closer to more individualized
treatment approaches. The cases described herein show that a
detailed molecular analysis consisting of both EGFR and
k-ras mutation analysis, together with array CGH, can help
clinicians to determine the appropriate stage and treatment for
patients with lung cancer presenting with multiple pulmonary
nodules.
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